Shareholders Foundation, Inc.

Evolus, Inc. (NASDAQ:EOLS) Long Term Shareholder Notice: Investigation of Potential Wrongdoing

An investigation on behalf of current long term investors in Evolus, Inc. (NASDAQ:EOLS) shares over possible breaches of fiduciary duty by certain officers and directors was announced.

 

San Diego, CA -- (SBWIRE) -- 02/03/2021 -- An investigation was announced over possible breaches of fiduciary duties by certain directors of Evolus, Inc.

Investors who are current long term investors in Evolus, Inc. (NASDAQ: EOLS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for investors in Evolus, Inc. (NASDAQ: EOLS stocks follows a lawsuit filed against Evolus, Inc. (NASDAQ: EOLS over alleged securities laws violations. The investigation on behalf of current long term investors in Evolus, Inc. (NASDAQ: EOLS stocks, concerns whether certain Evolus, Inc. (NASDAQ: EOLS officers and directors are liable in connection with the allegations made in that lawsuit.

The plaintiff alleges that Evolus made false and misleading statements to the public and failed to disclose that the real source of botulinum toxin bacterial strain as well as the manufacturing processes used to develop Jeuveau™ originated with and were misappropriated from Medytox, that sufficient evidentiary support existed for the allegations that Evolus misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau™, that as a result, Evolus faced a real threat of regulatory and/or court action, prohibiting the import, marketing, and sale of Jeuveau™, that which in turn seriously threatened Evolus' ability to commercialize Jeuveau™ in the United States and generate revenue, and that any revenues generated from the sale of Jeuveau™ were based on Evolus' unlawful activities, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox.

Those who purchased shares of Evolus, Inc. (NASDAQ: EOLS) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.